Good day everyone and welcome to the Human Genome Sciences' Fourth Quarter 2011 and Full Year Financial Results Webcast. Today's webcast is being recorded. At this time, I will turn things over to Mr. Thomas Watkins. Please go ahead Mr. Watkins.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.
We look at how a biotech ETF holds up in an iffy climate for those stocks.
Equity valuations as a whole have barely budged in 2005, but the market remains a bit on the pricey side when comparing to Morningstar's collective fair value estimates (To see more on Morningstar's perspective on market valuations, check out our Market Valuation Graph ). The median stock in our ...
Health care, energy, and tech--where the big companies have the cash, and the mid- and small companies have a lot of growth--are ripe for continued M&A activity, says Legg Mason ClearBridge's Evan Bauman.
High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.